$MRK has released its Q4 results, reflecting strong growth fueled by key products like KEYTRUDA and WINREVAIR, although GARDASIL faced challenges in China. Key stats reveal total revenues at $15.6 billion (+7%) and EPS of $1.72. The ongoing supply chain dynamics and regulatory changes pose risks, particularly for GARDASIL, while oncology and animal health present growth opportunities. The pipeline remains robust with many potential blockbusters on the horizon. Check details in http://valueverge.com/MRK.